Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R46 | P59540 | 8/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.32 |
| ▸ | TAS2R31 | P59538 | 2/20 | 0.32 |
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9240553 | 1.00 | TAS2R46 (0.47) | TAS2R46MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL8635163 | 1.00 | TAS2R46 (0.47) | TAS2R46MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL8628231 | 1.00 | TAS2R46 (0.47) | TAS2R46MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL754420 | 1.00 | TAS2R46 (0.47) | TAS2R46MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL9244208 | 1.00 | TAS2R46 (0.47) | TAS2R46MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL24026904 | 1.00 | TAS2R46 (0.47) | TAS2R46MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL13478756 | 1.00 | TAS2R46 (0.47) | TAS2R46MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL18629658 | 1.00 | TAS2R46 (0.47) | TAS2R46MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL21316644 | 1.00 | TAS2R46 (0.47) | TAS2R46MEN1KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL8632758 | 1.00 | TAS2R46 (0.47) | TAS2R46MEN1KMT2ACYP1A2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118157-A1 | Processes For Production Of Wine Lactone And Its Intermediates And Application Of The Lactone | SAN-EI GEN F.F.I. INC. (JP) | 2009-05-07 | — | — | US | disclosed |
| EP-1787975-A1 | PROCESSES FOR PRODUCTION OF WINE LACTONE AND ITS INTERMEDIATES AND APPLICATION OF THE LACTONE | SAN-EI GEN F.F.I., INC. (JP) | 2007-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118157-A1 | Processes For Production Of Wine Lactone And Its Intermediates And Application Of The Lactone | DCXR, COASY, AKR7A2 | TAS2R46 3485/4885MEN1 690/4885KMT2A 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.